Product Information
EZETIMIBE-SIMVASTATIN 10-40 MG is a generic product labeled by Ascend Laboratories, LLC, priced at $0.1830 per EA under NDC 67877050990. Its NADAC has been published 443 times since Apr 11, 2018.
FDA first approved this application on Dec 22, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 40 mg/1; mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877050990
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EZETIMIBE; SIMVASTATINApproval Type
Generic (ANDA)
FDA Application
ANDA209222FDA Approved
12/22/2017
TE Code
AB
On Market Since
12/24/2017
Pharmacological Classes
Price Statistics
The NADAC for EZETIMIBE-SIMVASTATIN 10-40 MG has been published 443 times since Apr 11, 2018, and over the history we have for it it has declined 93.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1830 per EA |
|---|---|
| All-time high | $2.7018 (Apr 11, 2018) |
| All-time low | $0.1830 (Sep 23, 2026) |
| 52-week high | $0.5024 |
| 52-week low | $0.1830 |
| Median price | $0.7163 |
| Average price | $1.0196 |
| Largest weekly change | +78.2% (May 18, 2022) |
| Weeks tracked | 443 |
| Tracking since | Apr 11, 2018 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ezetimibe and Simvastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dietary Cholesterol Absorption Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EZETIMIBE-SIMVASTATIN 10-40 MG?
The current National Average Drug Acquisition Cost (NADAC) for EZETIMIBE-SIMVASTATIN 10-40 MG, manufactured by Ascend Laboratories, LLC, is $0.1830 per EA (NDC 67877050990), effective Sep 30, 2026.
How has the price of EZETIMIBE-SIMVASTATIN 10-40 MG changed over time?
Over the history we have for it, the NADAC for EZETIMIBE-SIMVASTATIN 10-40 MG has declined 93.2%. It has been tracked across 443 weekly CMS publications since Apr 11, 2018.
What are the highest and lowest recorded NADAC prices for EZETIMIBE-SIMVASTATIN 10-40 MG?
Since Apr 11, 2018, the NADAC for EZETIMIBE-SIMVASTATIN 10-40 MG has ranged from a low of $0.1830 (Sep 23, 2026) to a high of $2.7018 (Apr 11, 2018), with a median of $0.7163 per EA.
Are there cheaper alternatives to EZETIMIBE-SIMVASTATIN 10-40 MG?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as EZETIMIBE-SIMVASTATIN 10-40 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures EZETIMIBE-SIMVASTATIN 10-40 MG?
EZETIMIBE-SIMVASTATIN 10-40 MG (NDC 67877050990) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.